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Inka Miñambres1 and Antonio Pérez1,2*
Abstract 
Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their phar-
macokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide 
and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). In 
clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients 
who would benefit more from one or another based on characteristics such as previous treatment and the predomi-
nance of fasting or postprandial hyperglycemia. In the present article we examine available data on the pharmacoki-
netic characteristics of the various GLP-1 agonists and compare their effects with respect to the main parameters 
used to evaluate glycemic control. The article also analyzes whether the differences between the different GLP-1 
agonists justify their classification as basal or prandial.
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Background
In contrast to most previous recommendations on the 
treatment of patients with type 2 diabetes, which were 
generally aimed at harmonizing and reducing variabil-
ity in clinical practice, current guidelines advocate an 
individualized approach [1]. Such an approach affects 
the choice of medication and the setting of objectives 
for control of glycemia, taking into account the impact 
of comorbid conditions, age, the patient’s attitudes and 
wishes, available resources, and support systems. The 
patient thus becomes a “partner” in decision-making 
under the guidance of an experienced health care profes-
sional. In the absence of contraindications, metformin 
continues to be the glucose-lowering drug of choice. 
Selection of a second agent for combination with met-
formin requires the physician to weigh up the advantages 
and disadvantages of each drug for the patient, taking 
into account individual needs and characteristics.
In the context of personalized treatment as a key strat-
egy in the management of patients with type 2 diabetes, 
the increasing availability of glucagon-like peptide (GLP) 
1 receptor agonists with different pharmacokinetic prop-
erties means that the appropriateness of the drug consid-
ered should be based on a series of factors: the patient’s 
specific needs and characteristics, pharmacokinetic 
properties, antihyperglycemic efficacy, effects on asso-
ciated processes, and safety profile. A certain degree of 
controversy surrounds the attempt to classify GLP-1 
receptor agonists not only as short- and long-acting, but 
also as basal and prandial, with the aim of basing the 
selection on whether the primary objective is to control 
basal or postprandial hyperglycemia.
The present article examines available data on the phar-
macokinetic characteristics of the various GLP-1 ago-
nists and compares their effects with respect to the main 
parameters used to evaluate glycemic control. The article 
also aims to consider whether the differences between 
the different GLP-1 agonists and their application in the 
treatment of patients with type 2 diabetes justify their 
classification as basal and prandial.
Role of basal and prandial hyperglycemia in the treatment 
of type 2 diabetes
HbA1c is considered to play a key role in the develop-
ment and progression of the complications of diabetes. 
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Since HbA1c values are determined by both basal and 
prandial components of hyperglycemia, the most suit-
able approach to reducing HbA1c in clinical practice 
should take into account both components [2]. How-
ever, the role played by each component varies widely 
between patients and even within the same patient at 
different stages of the disease. Furthermore, these roles 
depend on the degree of glycemic control and the treat-
ment the patient receives [3, 4]. Monnier et al. [3] found 
that in type 2 diabetic patients managed with diet and/
or antidiabetic drugs, the relative contribution of post-
prandial hyperglycemia was greater in patients with good 
glycemic control, whereas that of basal hyperglycemia 
was greater in patients with poor glycemic control. In 
patients treated with oral antihyperglycemic drugs, Rid-
dle et al. [4] showed that the relative contribution of basal 
hyperglycemia to HbA1c was 76–80% before intensifi-
cation with insulin and 31.5–41% after 24–28  weeks of 
treatment with basal insulin. Moreover, since the main 
determinant of postprandial hyperglycemia is prepran-
dial hyperglycemia, treatment of basal hyperglycemia is 
the most efficacious way to control postprandial hyper-
glycemia [5]. Finally, most major studies on the efficacy of 
glycemic control are based on fasting blood glucose and 
HbA1c targets. In addition, a study on patients with type 
2 diabetes treated with insulin after acute myocardial 
infarction showed that insulin therapy focusing on post-
prandial hyperglycemia provided no benefit over insulin 
treatment with preprandial glucose targets [6]. These 
arguments, together with the greater convenience and 
lower variability and costs of monitoring fasting blood 
glucose, justify the use of fasting glucose as a means of 
monitoring treatment. Nevertheless, when basal hyper-
glycemia is controlled and there is a discrepancy between 
basal/preprandial values and HbA1c, monitoring and 
control of postprandial hyperglycemia should be taken 
into consideration when attempting to achieve HbA1c 
targets [2].
Glucose homeostasis: role and differences between GLP‑1 
receptor analogs
The discovery of the incretin effect arose from the 
observation that oral administration of glucose gener-
ates a more pronounced insulin response than intrave-
nous administration of the same quantity of glucose [7] 
and accounts for approximately 50–70% of total insu-
lin secretion. The main intestinal peptides responsible 
for the incretin effect are gastric inhibitory polypeptide 
(GIP) and GLP-1. Given that the insulinotropic effect of 
GLP-1 is preserved in individuals with diabetes [8], this 
hormone has been investigated with the aim of identify-
ing new antihyperglycemic drugs. The currently available 
drugs that act by boosting the incretin effect comprise 
dipeptidyl-peptidase-IV (DPP-IV) inhibitors and GLP-1 
receptor agonists.
GLP-1 receptor agonists are best known for their insu-
linotropic effect but only when glucose levels are ele-
vated, thus offering the potential to lower plasma glucose 
while reducing the risk of hypoglycemia [9]. Further-
more, GLP-1 receptor agonists act against other abnor-
malities present in individuals with type 2 diabetes and 
included in the so-called ominous octet of diabetes [10]. 
Thus, GLP-1 receptor agonists inhibit secretion of gluca-
gon by pancreatic α cells, slow gastric emptying, and 
induce satiety by acting on the central nervous system 
[11]. These actions of GLP-1 receptor agonists contribute 
to their effects on glycemia and weight loss.
In this study, we focus on the differences between the 
various agonists in terms of pharmacokinetics, phar-
macodynamics, and, in particular, on the effects on the 
parameters used to evaluate glycemic control. Table  1 
classifies GLP-1 receptor agonists into short- and long-
acting agents and summarizes the main differences 
between them.
Differences in pharmacokinetics/pharmacodynamics
Several GLP-1 receptor agonists are available for treat-
ment of type 2 diabetic patients. The drugs authorized for 
clinical use include exenatide, exenatide-LAR, liraglutide, 
lixisenatide, albiglutide, and dulaglutide. Based on their 
pharmacokinetic/pharmacodynamic profile, these drugs 
are usually classified as short-acting GLP-1 receptor ago-
nists (exenatide and lixisenatide) or long-acting GLP-1 
receptor agonists (exenatide-LAR, liraglutide, albiglu-
tide, and dulaglutide). The main difference between the 
two groups is that when administered according to their 
dosing intervals, short-acting agonists are subject to wide 
fluctuations in the plasma concentration of the active 
compound, while long-acting agonists exert a more con-
stant effect on the GLP-1 receptor [11].
The natural molecule of human GLP-1 has a plasma 
half-life of 2–3 min owing to its rapid inactivation by the 
enzyme DPP-IV [12, 13]. Both exenatide and lixisenatide 
are synthesized through a modification in the N-termi-
nal portion of the GLP-1 molecule that makes the drugs 
more resistant to this degradation by DPP-IV and pro-
longs their half-life to 2–4 h [14]. Although the half-life 
of both molecules is similar, exenatide is administered 
every 12 h whereas lixisenatide is taken once daily. In the 
case of long-acting GLP-1 receptor agonists, the mecha-
nism that enables more stable and prolonged concentra-
tions of the active compound is different. For liraglutide, 
the addition of a fatty acid chain bound non-covalently 
to the GLP-1 analog enables the drug to bind to plasma 
albumin, ensuring that only a small percentage circu-
lates freely and can be eliminated by the kidneys. Thus, 
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the elimination kinetics of liraglutide depends on the rate 
of dissociation between GLP-1 and albumin, conferring 
a half-life of approximately 12 h with a single daily sub-
cutaneous dose [15, 16]. Exenatide-LAR, on the other 
hand, is designed in such a way that the active GLP-1 is 
encapsulated in poly(d,l lactic-co-glycolic acid) micro-
spheres enabling sustained release of the drug from the 
subcutaneous reservoir generated at the injection site. 
Consequently, when the drug is administered weekly, sta-
ble concentrations are reached 6–8 weeks after initiation 
Table 1 Main differences between short- and long-acting GLP-1 receptor agonists
Differences expressed as mean (SD)
Differences are significant unless otherwise indicated (NS)
a Postprandial hyperglycemia at meal after administration of the drug
b Short duration of the study (28 days)
c Change in postprandial glycemia at 2 h
d Mean difference between treatments (exenatide–liraglutide)
e Change in maximum postprandial glucose excursion
Short‑acting Long‑acting
Drugs Exenatide
Lixisenatide
Liraglutide
Exenatide-LAR
Albiglutide
Dulaglutide
Half-life 2–5 h 12 h to several days
Increased secretion of insulin + ++
Decreased secretion of glucagon + +
Decreased gastric emptying ++ +
Decreased fasting plasma glucose + ++
Decreased postprandial glycemia +/++a +a
Weight loss + +/++
Effects (head-to-head studies)
 Reduction in HbA1c
  Exenatide–exenatide-LAR −1.5% (0.1) −1.9% (0.1)
  Exenatide–liraglutide −0.79% (0.08) −1.12% (0.08)
  Lixisenatide–liraglutide Not evaluableb Not evaluableb
  Exenatide–dulaglutide −0.99% (0.06) −1.51% (0.06)
 Reduction in fasting plasma glucose
  Exenatide–exenatide-LAR −1.4 (0.2) mmol/L −2.3 (0.2) mmol/L
  Exenatide–liraglutide −0.6 (0.2) mmol/L −1.61 (0.2) mmol/L
  Lixisenatide–liraglutide −0.34 (0.15) mmol/L −1.3 (0.15) mmol/L
  Exenatide–dulaglutide −1.33 (0.11) mmol/L −2.39 (0.11) mmol/L
 Reduction in hyperglycemia after breakfast
  Exenatide–exenatide-LAR –6.9 (0.5) mmol/Lc –5.3 (0.5) mmol/Lc
  Exenatide–liraglutide –1.33 mmol/Ld
  Lixisenatide–liraglutide –3.9 (0.2) mmol/Le –1.4 (0.2) mmol/Le
  Exenatide–dulaglutide Similar reduction
 Reduction in hyperglycemia after lunch and dinner
  Exenatide–exenatide-LAR Not evaluable
  Exenatide–liraglutide No differences in meals
  Lixisenatide–liraglutide Lower glucose levels with liraglutide
  Exenatide–dulaglutide Higher glucose levels with exenatide
 Weight loss
  Exenatide–exenatide-LAR –3.6 (0.5) kg –3.7 (0.5) kg (NS)
  Exenatide–liraglutide –2.87 (0.33) kg –3.24 (0.33) kg (NS)
  Lixisenatide–liraglutide Not evaluableb Not evaluableb
  Exenatide–dulaglutide –1.07 (0.29) kg –1.3 (0.29) kg
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of therapy [17, 18]. Albiglutide is the product of fusion 
of two modified human GLP-1 [7–36] molecules to 
albumin. A single amino acid substitution of alanine to 
glycine at position 8 confers resistance to hydrolysis by 
DDP-IV and ensures a half-life of approximately 5  days 
[19]. Finally, dulaglutide consists of two identical chains 
of N-terminal GLP-1 joined by a disulfide bridge, each 
of which is bound covalently by means of a small bind-
ing peptide to a modified human immunoglobulin heavy 
chain. This modification confers resistance to degrada-
tion by DPP-IV and ensures the sustained release that 
accounts for the 5-day half-life [20].
The various pharmacokinetic characteristics of the 
different GLP-1 receptor agonists lead to differences in 
pharmacodynamics. Long-acting analogs can maintain 
high GLP-1 levels and stimulate secretion of insulin for 
24  h, even during fasting periods, resulting in a greater 
reduction in basal hyperglycemia. The effect of these 
GLP-1 receptor agonists on postprandial hyperglyce-
mia can be attributed mainly to suppression of glucagon 
secretion, reduced appetite, and slower gastric emptying.
The effect of short-acting GLP-1 receptor agonists on 
insulin secretion during the fasting period is less pro-
nounced than that of long-acting agonists, whereas the 
effect on gastric emptying is more pronounced [21, 22]. 
This difference in the effects on gastric emptying between 
short and long-acting GLP-1 receptor agonists can be 
attributed to tachyphylaxis, which occurs when stimula-
tion of the receptor is constant—as is the case with long-
acting agonists—but not when stimulation is intermittent 
[23]. The more pronounced effect on gastric emptying is 
the main reason for the greater efficacy of short-acting 
agonists in reducing postprandial hyperglycemia in the 
meal immediately following their administration [24, 25].
Effects of GLP‑1 agonists on HbA1c and basal 
and postprandial hyperglycemia
The effects of the various GLP-1 receptor agonists on 
glucose levels have been analyzed in phase III placebo-
controlled randomized trials within the framework of 
drug development programs such as AMIGO (exena-
tide), DURATION (exenatide-LAR), Get Goal (lixisena-
tide), LEAD (liraglutide), HARMONY (albiglutide), and 
AWARD (dulaglutide). All of these agents reduce HbA1c, 
basal hyperglycemia, and postprandial hyperglycemia. 
However, it is difficult to draw comparisons between 
them, since the studies were performed in different pop-
ulations. In addition, the variables analyzed and the way 
they are expressed also differ between the studies. For 
example, the effects on postprandial hyperglycemia were 
evaluated after a test meal or after the patient’s usual 
meals and not always at the same time of the day in all 
the trials. In some cases, postprandial hyperglycemia is 
expressed as the peak glucose value after meals, whereas 
in others it is expressed as postprandial glucose excur-
sion; in addition, the results are expressed as the abso-
lute effect or as the difference with respect to placebo. 
Consequently, it is extremely difficult to compare find-
ings between studies, and the data provided by recently 
published reviews [26–29] do not clarify these findings, 
since the confusion over terminology and the way the 
results are expressed remains unresolved or is simply 
disregarded.
Taken together, the different GLP-1 receptor agonists 
decrease HbA1c by around 1% (0.3–1.3%), whereas the 
reduction in fasting plasma glucose ranges from 0.2 
to 2.1  mmol/L (3.6–37.8  mg/dL). In studies evaluating 
the effect on postprandial hyperglycemia, the decrease 
observed was 1.8–6.2  mmol/L (32.4–111.6  mg/dL) [28, 
30–32]. The reduction in HbA1c and basal hypergly-
cemia is generally greater with long-acting agonists 
whereas the reduction in postprandial hyperglycemia in 
the meal immediately following administration is greater 
with short-acting agonists.
In this context, available data from head-to-head 
studies may help to clarify the differences between the 
different GLP-1 receptor agonists. In addition, the post-
prandial effect should be evaluated throughout the day 
and not only after the first meal of the day, as is the case 
in some of the trials published.
Comparison between GLP‑1 analogs in head‑to‑head 
studies
Exenatide vs exenatide‑LAR
The DURATION-1 study [17] and DURATION-5 study 
[33] compared exenatide 10 µg/12 h with exenatide-LAR 
2  mg/week. The results of DURATION-1 showed that 
after 30 weeks of follow-up, the reduction in HbA1c was 
greater with exenatide-LAR (−1.9 vs −1.5%; p = 0.0023), 
as was the decrease in fasting plasma glucose (−2.3 vs 
−1.4 mmol/L; −41.4 vs 25.2 mg/dL; p < 0.05); however, 
the decrease in postprandial glycemia after a standard 
breakfast was greater with exenatide than with exena-
tide-LAR (−6.9 vs −5.3  mmol/L; 124.2 vs 95.4  mg/dL; 
p =  0.0124). The analysis of gastric emptying evaluated 
using paracetamol absorption showed that emptying 
was slower with twice-daily exenatide [17]. The results of 
DURATION-5 showed that the reduction in HbA1c was 
greater with exenatide-LAR than with twice-daily exena-
tide. In this study, the effect on postprandial hypergly-
cemia was not analyzed [33]. No differences in terms of 
weight decrease were found in either study.
Exenatide vs lixisenatide
GetGoal X was a noninferiority trial comparing lixisena-
tide with exenatide. The reduction in HbA1c was 0.79 and 
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0.96%, respectively, and the reduction in fasting plasma 
glucose was 1.3 and 1.49  mmol/L (23.4 and 26.82  mg/
dL), thus confirming that lixisenatide was not inferior 
to exenatide. Differences in postprandial glycemia were 
not analyzed, and a greater decrease in body weight was 
observed with exenatide (−3.98 vs −2.96 kg) [34].
Lixisenatide vs liraglutide
In a randomized trial, Kapitza et  al. [35] compared the 
effect of lixisenatide and liraglutide on postprandial 
hyperglycemia at 28  days. The results show a greater 
reduction in maximum postprandial hyperglycemia 
after a standardized breakfast with lixisenatide (−3.9 vs 
−1.4 mmol/L; −70.2 vs −25.2 mg/dL; p < 0.0001). How-
ever, the 24-h pharmacodynamic profile of both drugs at 
days 1 and 28 showed that despite differences in glucose 
levels during the first 4 h after breakfast in favor of lixi-
senatide, from 4.5 h onward, postprandial hyperglycemia 
was lower in patients treated with liraglutide. Liraglutide 
led to greater decreases in basal plasma glucose (−1.3 
vs −0.3  mmol/L; 23.4 vs 5.4  mg/dL; p  <  0.001), HbA1c 
(−0.51 vs −0.32%; p  <  0.01), and body weight (−2.4 vs 
−1.6 kg; p < 0.001).
Liraglutide vs exenatide
The LEAD-6 study compared liraglutide with exenatide 
in terms of the effects of each on blood glucose param-
eters [22]. The results showed that liraglutide led to a 
greater decrease in HbA1c (−1.12 vs −0.79%; p < 0.0001) 
and fasting plasma glucose (−1.61 vs 0.6 mmol/L; −28.9 
vs −10.8 mg/dL; p < 0.0001). Self-monitoring of plasma 
glucose at 26 weeks showed that the reduction in hyper-
glycemia after breakfast and dinner was greater with 
exenatide, with the difference between treatments esti-
mated at 1.33  mmol/L (23.9  mg/dL) after breakfast 
(p < 0.0001) and 1.01 mmol/L (18.2 mg/dL) after dinner 
(p < 0.0005). No differences were observed in glucose lev-
els after lunch or in weight loss.
Liraglutide vs exenatide‑LAR
The DURATION-6 study showed that liraglutide was 
more efficacious than exenatide-LAR in reducing HbA1c 
(−1.48 vs −1.28%; p  =  0.0018) and basal plasma glu-
cose (−2.12 vs −1.76  mmol/L; −38.16 vs −31.68  mg/
dL; p < 0.001). Liraglutide also led to greater weight loss 
than exenatide-LAR (−3.57  kg vs −2.68  kg; p  <  0.001). 
The effect on postprandial hyperglycemia was not stud-
ied [36].
Albiglutide vs liraglutide
In the HARMONY 7 study [37], patients who received 
once-daily liraglutide had greater reductions in HbA1c 
(−0.99% vs −0.78), fasting plasma glucose (−1.68 vs 
−1.22  mmol/L; −30.24 vs 21.96  mg/dL; p  <  0.05), and 
weight loss (−2.19 vs −0.64 kg; p < 0.0001) than did those 
who received once-weekly albiglutide. No data were pro-
vided for postprandial hyperglycemia.
Dulaglutide vs exenatide
In the AWARD-1 study [30], dulaglutide led to a greater 
reduction in HbA1c (−1.51 vs −0.99%; p  <  0.001) and 
fasting plasma glucose (−2.38 vs –1.33 mmol/L; −43 vs 
−24  mg/dL; p  <  0.001). Data from capillary blood glu-
cose monitoring at 26 weeks showed that the reduction 
in postprandial glycemia at breakfast was similar for both 
exenatide and dulaglutide, whereas the reduction in post-
prandial hyperglycemia during the rest of the day was 
superior with dulaglutide (data not shown). No differ-
ences in weight were recorded.
Dulaglutide vs liraglutide
The AWARD-6 study [38] showed that the decrease in 
HbA1c, fasting plasma glucose, and postprandial glyce-
mia was similar with dulaglutide and liraglutide, although 
weight loss was greater with liraglutide (−2.9  kg vs 
−3.61 kg; p < 0.05).
Effect of GLP‑1 analogs on daily postprandial 
hyperglycemia
In order to evaluate the action of a drug on postprandial 
hyperglycemia, especially when it is not administered 
before each meal, it is necessary to determine the effect 
on postprandial hyperglycemia throughout the day, not 
only immediately after the drug is administered.
In most studies on GLP-1 receptor agonists, the effects 
on postprandial glycemia are limited to breakfast. How-
ever, although available data are scarce, findings from 
some studies can better explain the effect of the drug 
at other points during the day. In their randomized 
study, Lorenz et  al. [25] compared the effect of morn-
ing lixisenatide with placebo on postprandial hyper-
glycemia at breakfast, lunch, and dinner. The results 
showed a significant reduction in postprandial hyper-
glycemia throughout the day with lixisenatide, although 
the reduction was very marked at the glucose peak 
after breakfast (−3.9 ±  0.6  mmol/L; −70.2 ±  10.8  mg/
dL) and less marked after lunch (−1.2  ±  0.7  mmol/L; 
−21.6 ±  12.6  mg/dL) and dinner (−0.6 ±  0.7  mmol/L; 
−10.8 ± 12.6 mg/dL). Kapitza et al. [35] found lixisena-
tide to be clearly superior to liraglutide for reducing post-
prandial glycemia after breakfast [−3.9 vs 1.4  mmol/L 
(−70.2 vs 25.2 mg/dL) for the change in maximum glu-
cose excursion; p  <  0.0001], although capillary glucose 
monitoring values during the rest of the day were lower 
with liraglutide, including the values recorded after 
lunch and dinner. In the LEAD-6 study, which compared 
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liraglutide with exenatide, the reduction in hyperglyce-
mia after breakfast and dinner was greater with exena-
tide, whereas no differences were observed after lunch 
[22]. Finally, in the AWARD-1 study [30], the reduction 
in hyperglycemia after breakfast was similar with exena-
tide and dulaglutide, whereas the effect of dulaglutide 
was superior after lunch and dinner. These findings high-
light the more pronounced postprandial effect of short-
acting analogs, although this more pronounced effect 
seems to be limited to the meal that is eaten immediately 
after administration of the drug.
As stated above, after initiation of treatment with 
basal insulin, which decreases fasting glucose, the rela-
tive contribution of postprandial hyperglycemia to total 
hyperglycemia increases from 20–24% to 59–69% [4]. 
GLP-1 receptor agonists stimulate glucose-medicated 
insulin secretion, suppress glucagon secretion, delay gas-
tric emptying, and decrease appetite, thus explaining the 
considerable effect of these drugs on postprandial hyper-
glycemia and weight loss. Therefore, patients treated 
with basal insulin also seem to be suitable candidates for 
GLP-1 receptor agonists, and combining GLP-1 receptor 
agonists with basal insulin offers an alternative approach 
to intensification of insulin therapy when basal insu-
lin is insufficient. Systematic reviews and meta-analyses 
of prospective studies [39–42] demonstrate that GLP-1 
receptor agonists added to basal insulin decrease post-
prandial glucose levels, HbA1c levels, body weight, and 
basal insulin requirements without increasing the risk 
of major hypoglycemic events. Randomized studies that 
evaluate the effect of GLP-1 receptor agonists combined 
with basal insulin [43–46] confirm these findings. Buse 
et  al. [43] found that the addition of exenatide to basal 
insulin led to a reduction in HbA1c that was significantly 
greater than with placebo (−1.74 vs −1.04%; p < 0.001), 
with a lower increase in the dose of insulin. In addition, 
data on self-monitoring of capillary glucose show signifi-
cant decreases in postprandial glucose levels at breakfast 
and dinner. In the three Get Goal studies [44–46], addi-
tion of lixisenatide to basal insulin led to an improvement 
in HbA1c and hyperglycemia after breakfast, as well as 
weight loss. In addition, some randomized controlled tri-
als have compared GLP-1 receptor agonists to prandial 
insulin in patients treated with a basal insulin regimen. 
Diamant et al. [47] analyzed the addition of exenatide in 
patients treated with insulin glargine and found a similar 
reduction in HbA1c with respect to addition of insulin 
lispro; however, weight loss and the reduction in fast-
ing plasma glucose were greater with exenatide. Mathieu 
et al. [48] compared the effect of liraglutide with that of 
single-dose insulin aspart administered with the main 
meal of the day in patients who had previously received 
insulin degludec and metformin. The results revealed a 
greater reduction in HbA1c and weight loss in patients 
treated with liraglutide. Finally, the HARMONY-6 study 
[49], which compared albiglutide with insulin lispro in 
patients treated with insulin glargine, revealed a similar 
reduction in HbA1c, but with fewer cases of hypogly-
cemia and greater weight loss. Overall, as stated in the 
meta-analysis of Eng et  al. [42], compared with basal 
bolus insulin regimens, the combination of basal insulin 
and a GLP-1 receptor agonist leads to a mean reduction 
in HbA1c of −0.1% (−0.17 to −0.02%), with a lower rela-
tive risk of hypoglycemia (0.67; 0.56 to 0.80) and a reduc-
tion in mean weight loss (−5.66 kg; −9.8 to −1.51).
The data presented here show the efficacy of short-term 
treatment with GLP-1 receptor agonists compared with 
placebo or short-acting insulin in patients taking basal 
insulin. However, our findings are limited by the lack of 
data on the long-term effects of GLP-1 receptor agonists 
used in combination with insulin. Furthermore, data ena-
bling us to predict which individuals will respond or not 
to GLP-1 agonists are very limited [50].
There is emerging data suggesting efficacy differences 
between GLP-1 receptor agonists according to pancreatic 
insulin reserve. In a recent post hoc study of GetGoal-
M and getGoal-S trials, lixisenatide has demonstrated 
its efficacy across different stages of beta cell dysfunc-
tion [51], while long-term efficacy of liraglutide seems 
to be related to β-cell function [52]. These findings may 
reflect the fact that short-acting analogs exert most of 
their effects on glycemia through the decrease in gastric 
emptying as stated before [24, 25], whereas long-acting 
analog effects are more dependent of insulin secretion.
Therefore, the possibility of differentiating between 
early responders and nonresponders to different GLP-1 
receptor agonists and establishing the efficacy and safety 
of these agents in the long term has yet to be clarified. In 
addition, their role in patients receiving basal bolus insu-
lin regimens warrants further study.
Effects of GLP‑1 receptor agonists on cardiovascular 
outcomes
At this time, there are three published CV safety out-
come trials for the GLP-1 receptor agonists: lixisenatide 
in acute coronary syndrome (ELIXA) trial [53], liraglu-
tide effect and action in diabetes: evaluation of CV out-
come results (LEADER) [54], and trial to evaluate CV 
and other long-term outcomes with semaglutide in sub-
jects with type 2 diabetes (SUSTAIN-6) [55] conducted 
with lixisenatide, liraglutide, and semaglutide and with a 
median follow-up of 2.1, 3.8 and 2.0  years, respectively. 
All of these studies were powered to assess non-inferior-
ity or to adequately detect differences between the drug 
and placebo on the 3-point major adverse cardiac events 
(MACE; cardiovascular death, nonfatal myocardial 
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infarction, or nonfatal stroke). The ELIXA trial included 
6068 patients with type 2 diabetes who had experienced 
an acute coronary event within 180  days prior to rand-
omization, and LEADER and SUSTAIN-6 trials enrolled 
9340 and 3297 adults with type 2 diabetes at high car-
diovascular risk, respectively. The ELIXA study dem-
onstrated cardiovascular safety, but not cardiovascular 
benefit of the short acting GLP-1 RA lixisenatide, while 
LEADER and SUSTAIN-6 trials showed that the long-
acting GLP-1 receptor agonists liraglutide and semaglu-
tide reduce cardiovascular risk.
The mechanisms for improved cardiovascular out-
comes with liraglutide and semaglutide but not with 
lixisenatide are not clear. All studies showed improved 
glycemic control, reduced body weight and systolic blood 
pressure, and increased heart rate. Moreover, differences 
in baseline patient characteristics, trial duration, and 
routine care do not seem to account for differences in 
cardiovascular outcomes. Previous studies showed possi-
ble beneficial effects on endothelial function and the CV 
system through direct effects mediated through GLP-1 
receptor-dependent and through independent mecha-
nisms [56]. Unlike those treated with liraglutide and 
semaglutide, patients treated with short-acting GLP-1 
RA lixisenatide are uncovered by the drug for most of the 
day. Thus, pharmacokinetic differences could play a role 
in the lower incidence of adverse CV outcomes with lira-
glutide and semaglutide, and its confirmation in the cur-
rently underway trials with other long-acting GLP-1 RA, 
would support a class effect of long-acting GLP-1 RA for 
cardiovascular outcomes.
Conclusions
This study raised the question of whether the differences 
between the different GLP-1 receptor agonists and their 
application in the treatment of patients with type 2 dia-
betes support their classification as basal and prandial. 
Given the available pharmacological and clinical data, 
we believe the most appropriate classification of GLP-1 
receptor agonists is as short-term and long-term agents. 
Both pharmacokinetic and pharmacodynamic data sup-
port this classification and make it possible to differenti-
ate between some of the drugs’ clinical effects. However, 
given the considerable differences between available 
agents and those currently under development, in the 
future it would probably be more appropriate to classify 
GLP-1 receptor agonists as short-acting, intermediate-
acting, and long-acting.
In contrast, unlike basal and prandial insulin, whose 
effects are clearly different, currently available data make 
it somewhat difficult to support the classification of 
GLP-1 receptor agonists into basal and prandial. In fact, 
if we were to draw an analogy, GLP-1 receptor agonists 
would be closer to intermediate-acting insulins, since 
both have a basal and prandial component that can vary 
over a 24-h period. To a greater or lesser extent, all GLP-1 
receptor agonists affect both the basal and prandial com-
ponents of hyperglycemia in patients with type 2 diabe-
tes, although the main mechanism by which they reduce 
postprandial hyperglycemia can differ between drugs and 
with the same drug administered at different mealtimes 
during the day. Therefore, the reduction in postprandial 
glycemia with short-acting agonists (exenatide, lixisena-
tide) seems to be more associated with gastric emptying 
during the meal immediately after administration. With 
long-acting agonists, however, most of the decrease in 
postprandial glycemia probably results from the decrease 
in preprandial glycemia—the main component of post-
prandial hyperglycemia—and the glucagon suppression 
that is common to all GLP-1 receptor agonists. The effect 
on preprandial hyperglycemia may also be the most rel-
evant mechanism of short-acting receptor agonists in the 
reduction of postprandial hyperglycemia at meals where 
the drug is not administered.
In addition, as mentioned above, in most patients with 
type 2 diabetes who are candidates for a second or third 
antihyperglycemic drug, the main abnormality is basal 
hyperglycemia [4]. In this context, control of basal gly-
cemia is the most efficacious way to treat postprandial 
glycemia [5]. Nevertheless, in patients treated with basal 
insulin and in cases where the glycemic profile shows a 
clear predominance of prandial hyperglycemia, a drug 
with a more specific action against this abnormality 
could prove useful.
In conclusion, GLP-1 receptor agonists cannot replace 
basal insulin or prandial insulin. Data enabling us to 
identify responders and nonresponders are scarce and, 
although the effect on glucagon suppression, gastric 
emptying, and appetite probably persists in patients with 
marked insulin deficiency, we do not have data on the 
durability of efficacy of GLP-1 receptor agonists during 
the course of type 2 diabetes. Therefore, continuation or 
discontinuation of treatment should be decided on an 
individual basis depending on the clinical response.
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